Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Department of Medicine, King Khalid University, Abha, Saudi Arabia.
Saudi J Gastroenterol. 2024 Jul 1;30(4):210-227. doi: 10.4103/sjg.sjg_50_24. Epub 2024 May 16.
Eosinophilic esophagitis is an antigen-mediated chronic inflammatory disorder that has risen in incidence and prevalence over the past 2 decades. The clinical presentation is variable and consists of mainly esophageal symptoms such as dysphagia, heartburn, food impaction, and vomiting. Current management relies on dietary elimination, proton-pump inhibitors, and topical corticosteroids with different response rates and relapses after treatment discontinuation. With a better understanding of the underlying pathophysiology, many molecules emerged recently as targeted treatment including dupilumab (IL4/IL13 blocker), as the first FDA-approved biological treatment, which has changed the management paradigm.
嗜酸性粒细胞性食管炎是一种抗原介导的慢性炎症性疾病,在过去 20 年中其发病率和患病率有所上升。临床表现多种多样,主要为食管症状,如吞咽困难、烧心、食物嵌塞和呕吐。目前的治疗方法主要是饮食排除、质子泵抑制剂和局部皮质类固醇,其治疗反应率和停药后复发率各不相同。随着对潜在病理生理学的更好理解,许多分子最近作为靶向治疗出现,包括度普利尤单抗(IL4/IL13 阻滞剂),这是首个获得 FDA 批准的生物治疗药物,它改变了治疗模式。